INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Narrative review / 2019

A review of 77 clinical studies highlights the lipid-lowering and insulin-resistance improving effects of berberine with low toxicity.

This review examined clinical trials on Berberis vulgaris and its alkaloid constituent berberine across electronic databases. Across 77 human clinical studies, lipid-lowering and insulin-resistance improving actions were the most frequently studied properties, alongside cardiovascular, anticancer, gastrointestinal, CNS, and endocrine applications. Berberine demonstrated very low toxicity at usual doses with no major side effects, though mild gastrointestinal reactions occurred in some patients.

Study type
Clinical review of clinical trials
Who was studied
Human subjects across 77 clinical studies
What was measured
Therapeutic uses including lipid-lowering, insulin resistance, cardiovascular, anticancer, and gastrointestinal effects, and toxicity

THE PAPER

Berberine and barberry (Berberis vulgaris): A clinical review.

Imenshahidi M, Hosseinzadeh H. Phytother Res, 2019.

PubMed 30637820 ↗DOI 10.1002/ptr.6252 ↗

Heart & arteriesDiabetes & blood sugarCancerGut & microbiomeOther health

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.